Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.26 USD
-0.12 (-8.70%)
Updated May 30, 2024 04:00 PM ET
After-Market: $1.27 +0.01 (0.79%) 6:28 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 161 - 180 ( 395 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Breaching the I/O Fort With a Weaponized IL-2; Assuming Coverage With a $125 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
We are placing shares of NKTR Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Q3 Inline, Guidance Raised; Most Impressive- NKTR-181 NDA Filing in April
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.